Lyell CEO Lynn Seely at #BIO24 (Brian Benton Photography)
June 17, 2025 11:29 AM EDTUpdated 02:25 PM
R&D

Lyell’s lym­phoma da­ta for re­cent­ly ac­quired CAR-T re­ceive luke­warm re­cep­tion on Wall Street

Max Gelman

Senior Editor

Lyell Im­munophar­ma’s re­cent­ly ac­quired CAR-T doesn’t ap­pear to im­press Wall Street.

The com­pa­ny said Tues­day that its dual-tar­get­ing CD19/CD20 CAR-T called …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

Dyne piv­ots on pri­ma­ry end­point, de­lays fil­ing for DM1 drug

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times